111 related articles for article (PubMed ID: 11557918)
21. Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers.
Kirchheiner J; Ufer M; Walter EC; Kammerer B; Kahlich R; Meisel C; Schwab M; Gleiter CH; Rane A; Roots I; Brockmöller J
Pharmacogenetics; 2004 Jan; 14(1):19-26. PubMed ID: 15128047
[TBL] [Abstract][Full Text] [Related]
22. Warfarin therapy in a patient homozygous for the CYP2C9 3 allele.
Ablin J; Cabili S; Lagziel A; Peretz H
Isr Med Assoc J; 2002 Feb; 4(2):139-41. PubMed ID: 11875991
[No Abstract] [Full Text] [Related]
23. The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol.
Thijssen HH; Verkooijen IW; Frank HL
Pharmacogenetics; 2000 Nov; 10(8):757-60. PubMed ID: 11186138
[No Abstract] [Full Text] [Related]
24. [Maintenance dose requirement for phenytoin is lowered in genetically impaired drug metabolism independent of concommitant use of other antiepileptics].
van der Weide J; Steijns LS; van Weelden MJ; de Haan K
Ned Tijdschr Geneeskd; 2001 Feb; 145(7):312-5. PubMed ID: 11234294
[TBL] [Abstract][Full Text] [Related]
25. Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics.
Hermans JJ; Thijssen HH
Br J Pharmacol; 1993 Sep; 110(1):482-90. PubMed ID: 8220911
[TBL] [Abstract][Full Text] [Related]
26. Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype.
Henne KR; Gaedigk A; Gupta G; Leeder JS; Rettie AE
J Chromatogr B Biomed Sci Appl; 1998 Jun; 710(1-2):143-8. PubMed ID: 9686881
[TBL] [Abstract][Full Text] [Related]
27. Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol.
Hermida J; Zarza J; Alberca I; Montes R; López ML; Molina E; Rocha E
Blood; 2002 Jun; 99(11):4237-9. PubMed ID: 12010835
[TBL] [Abstract][Full Text] [Related]
28. Cytochrome P450 2C9 polymorphism and acenocoumarol therapy.
Mark L; Marki-Zay J; Fodor L; Hajdara I; Paragh G; Katona A
Kardiol Pol; 2006 Apr; 64(4):397-402; discussion 403-4. PubMed ID: 16699986
[TBL] [Abstract][Full Text] [Related]
29. Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry.
Werner U; Werner D; Pahl A; Mundkowski R; Gillich M; Brune K
Biomed Chromatogr; 2002 Feb; 16(1):56-60. PubMed ID: 11816012
[TBL] [Abstract][Full Text] [Related]
30. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.
Kamali F; Khan TI; King BP; Frearson R; Kesteven P; Wood P; Daly AK; Wynne H
Clin Pharmacol Ther; 2004 Mar; 75(3):204-12. PubMed ID: 15001972
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic studies of enantiomers of ibuprofen and its chiral metabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes.
Karaźniewicz-Łada M; Luczak M; Główka F
Xenobiotica; 2009 Jun; 39(6):476-85. PubMed ID: 19480553
[TBL] [Abstract][Full Text] [Related]
32. Cytochrome P4502C9 genotype in Southeast Anatolia and possible relation with some serum tumour markers and cytokines.
Yilmaz N; Erbağci AB; Aynacioğlu AS
Acta Biochim Pol; 2001; 48(3):775-82. PubMed ID: 11833786
[TBL] [Abstract][Full Text] [Related]
33. Leu208Val and Ile181Leu variants of cytochrome P450 CYP2C9 are not related to the acenocoumarol dose requirement in a Spanish population.
Zarza J; Hermida J; Montes R; Alberca I; López ML; Rocha E
Blood; 2002 Jul; 100(2):734. PubMed ID: 12123234
[No Abstract] [Full Text] [Related]
34. Reply to rebuttal: Gene variants of the cytochrome P450 CYP2C9 affect oral anticoagulation with warfarin.
Margaglione M; Brancaccio V; Ciampa A; Di Minno G
Thromb Haemost; 2001 Sep; 86(3):938. PubMed ID: 11583336
[No Abstract] [Full Text] [Related]
35. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3.
Brandolese R; Scordo MG; Spina E; Gusella M; Padrini R
Clin Pharmacol Ther; 2001 Oct; 70(4):391-4. PubMed ID: 11673755
[TBL] [Abstract][Full Text] [Related]
36. Acenocoumarol stabilization is delayed in CYP2C93 carriers.
Schalekamp T; van Geest-Daalderop JH; de Vries-Goldschmeding H; Conemans J; Bernsen Mj Mj; de Boer A
Clin Pharmacol Ther; 2004 May; 75(5):394-402. PubMed ID: 15116052
[TBL] [Abstract][Full Text] [Related]
37. Stereoselective aspects in the pharmacokinetics and pharmacodynamics of acenocoumarol and its amino and acetamido derivatives in the rat.
Thijssen HH; Baars LG; Drittij-Reijnders MJ
Drug Metab Dispos; 1985; 13(5):593-7. PubMed ID: 2865109
[TBL] [Abstract][Full Text] [Related]
38. Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers.
Ma JD; Nafziger AN; Kashuba AD; Kim MJ; Gaedigk A; Rowland E; Kim JS; Bertino JS
J Clin Pharmacol; 2004 Jun; 44(6):570-6. PubMed ID: 15145963
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers.
Fischer TL; Pieper JA; Graff DW; Rodgers JE; Fischer JD; Parnell KJ; Goldstein JA; Greenwood R; Patterson JH
Clin Pharmacol Ther; 2002 Sep; 72(3):238-46. PubMed ID: 12235444
[TBL] [Abstract][Full Text] [Related]
40. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
Kirchheiner J; Kudlicz D; Meisel C; Bauer S; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2003 Aug; 74(2):186-94. PubMed ID: 12891229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
